论文部分内容阅读
目的:评价核素碘消融疗法联合放射线治疗在临床治疗分化型甲状腺癌中的应用价值。方法:对146例术后证实为分化型甲状腺癌的患者采用核素碘消融疗法及放射线治疗并服甲状腺激素抑制治疗,随访2～10年。结果:146例分化型甲状腺癌患者经1次治疗,完全清除残留甲状腺112例,不完全清除34例。8例治疗后发现新的转移灶。131碘对分化型甲状腺癌的180处转移灶,治疗后治愈或好转174处。结论:分化型甲状腺癌术后常规采用核素碘消融疗法联合放射线治疗,对于降低分化型甲状腺癌复发,降低转移发生的可能性,早期诊断隐匿性的转移灶,延长患者生存期起到重要作用。
Objective: To evaluate the value of radionuclide ablation combined with radiotherapy in the treatment of differentiated thyroid carcinoma. Methods: A total of 146 patients with differentiated thyroid carcinoma confirmed by surgery were treated with radionuclide ablation and radiotherapy and thyroid hormone suppressive therapy. The patients were followed up for 2 to 10 years. Results: One hundred and sixty-four patients with differentiated thyroid cancer underwent primary treatment, 112 cases of residual thyroid gland were completely eliminated and 34 cases were incompletely cleared. 8 cases of new metastases found after treatment. 131 iodine on differentiated thyroid cancer in 180 metastases, cured or improved after treatment 174. Conclusion: Radiotherapy with radionuclide ablation combined with radionuclide radiotherapy in differentiated thyroid carcinoma after conventional surgery may play an important role in reducing the recurrence of differentiated thyroid carcinoma, reducing the possibility of metastasis, early diagnosis of occult metastases and prolonging the survival of patients .